Market Overview

Bio-Rad Laboratories: Q3 Earnings Insights


Shares of Bio-Rad Laboratories (NYSE:BIO) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 86.34% year over year to $3.00, which beat the estimate of $1.80.

Revenue of $647,263,000 rose by 15.45% year over year, which beat the estimate of $570,580,000.


Bio-Rad Laboratories hasn't issued any earnings guidance for the time being.

Bio-Rad Laboratories hasn't issued any revenue guidance for the time being.

Recent Stock Performance

52-week high: $592.66

Company's 52-week low was at $309.38

Price action over last quarter: Up 8.22%

Company Overview

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.


Related Articles (BIO)

View Comments and Join the Discussion!

Posted-In: Earnings